What is the 13F Pro Quality Score for NGNE?

13F Pro ranks Neurogene Inc. (NGNE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NGNE's current score at https://13fpro.ai/company/NGNE (free sign-up required for the full ranking).

Which hedge funds own the most NGNE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NGNE include Samsara BioCapital,, Casdin Capital,, Redmile Group,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/NGNE as soon as new 13F filings post.

Where does 13F Pro source NGNE data?

All Neurogene Inc. fundamentals and ownership data come directly from SEC EDGAR. Neurogene Inc. files with the SEC under CIK 1404644. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NGNE in?

Neurogene Inc. (NGNE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NGNE research updated on 13F Pro?

NGNE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Neurogene Inc.(NGNE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1404644 NGNE stock profile & AI dashboard →

13F Pro Quality Score

27.4/100

Rank #2,434 of 2,777 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

9.1/100

Earnings Quality

15.3/100

Free Cash Flow

30.0/100

Institutional Flow

78.8/100

Revenue Scale

30.0/100

Dilution Risk

0.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why NGNE Scores 27/100

exact factor attribution · 2026-03-20

NGNE's composite is driven by institutional flow, held back by capital efficiency and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+1.4 pts

79th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-2.5 pts

1th pct

Profitability

-3.0 pts

30th pct

Free cash flow

-3.0 pts

30th pct

Scale

-3.0 pts

30th pct

Earnings quality

-3.5 pts

15th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.1 pts

9th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

NGNE Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Neurogene Inc. (NGNE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NGNE at 27.4/100 on a 32-signal composite quality model, placing it at rank #2,434 of 2,777 stocks — the bottom half of the AI-ranked universe. NGNE scores in the top quartile across institutional flow (78.8). Areas of concern include balance sheet strength (9.1) and earnings quality (15.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Neurogene Inc. reports net income of $-34.5M, free cash flow of $-24.1M. Top institutional holders of NGNE by reported 13-F value include Samsara BioCapital, Casdin Capital, Redmile Group, based on the most recent SEC filings. NGNE trades on the Nasdaq exchange and files with the SEC under CIK 1404644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NGNE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neurogene Inc. directly from SEC EDGAR. Neurogene Inc.'s 13F Pro composite quality score has ranged between 14 and 27 since 2026, currently 27.4 — an improving long-term trajectory across 24 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-34.5M

Free Cash Flow

Q2 2026

$-24.1M

ROIC

Q2 2026

-67.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-100.0% YoY

$0.00FY 2025

FY22 —FY23 $0.00FY24 $925.0KFY25 $0.00

Net Income

-20.2% YoY

$-90.4MFY 2025

FY22 $-55.2MFY23 $-36.3MFY24 $-75.1MFY25 $-90.4M

Operating Income

-25.1% YoY

$-103.3MFY 2025

FY22 $-56.5MFY23 $-55.6MFY24 $-82.6MFY25 $-103.3M

EPS (Diluted)

+0.9% YoY

$-4.24FY 2025

FY22 $-1.04FY23 —FY24 $-4.28FY25 $-4.24

Total Assets

-14.0% YoY

$288.6MFY 2025

FY22 $115.9MFY23 $222.6MFY24 $335.7MFY25 $288.6M

Op. Cash Flow

-9.3% YoY

$-77.2MFY 2025

FY22 $-52.8MFY23 $-51.4MFY24 $-70.6MFY25 $-77.2M

Free Cash Flow

-9.7% YoY

$-78.4MFY 2025

FY22 $-55.1MFY23 $-51.7MFY24 $-71.4MFY25 $-78.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00 -100.0%	$925.0K	$0.00	—	—	—
Net Income	$-90.4M -20.2%	$-75.1M -106.9%	$-36.3M +34.2%	$-55.2M +9.1%	$-60.7M -82.4%	$-33.3M
Operating Income	$-103.3M -25.1%	$-82.6M -48.6%	$-55.6M +1.7%	$-56.5M +6.9%	$-60.7M -80.0%	$-33.7M
EPS (Diluted)	$-4.24 +0.9%	$-4.28	—	$-1.04 +5.5%	$-1.10 -71.9%	$-0.64
Total Assets	$288.6M -14.0%	$335.7M +50.8%	$222.6M +92.0%	$115.9M -29.0%	$163.3M -22.4%	$210.5M
Operating Cash Flow	$-77.2M -9.3%	$-70.6M -37.3%	$-51.4M +2.7%	$-52.8M -11.1%	$-47.6M -93.5%	$-24.6M
Free Cash Flow	$-78.4M -9.7%	$-71.4M -38.0%	$-51.7M +6.0%	$-55.1M -8.3%	$-50.8M -89.7%	$-26.8M

Get alerted when NGNE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Neurogene Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NGNE

Samsara BioCapital, LLC
$54.0M1,717,127 sh
Casdin Capital, LLC
$48.6M1,545,361 sh
Redmile Group, LLC
$44.4M1,412,199 sh
RTW INVESTMENTS, LP
$42.8M1,362,456 sh
EcoR1 Capital, LLC
$40.0M1,271,342 sh
BlackRock, Inc.
$33.3M1,057,983 sh
BAKER BROS. ADVISORS LP
$31.2M991,691 sh
BALYASNY ASSET MANAGEMENT L.P.
$25.7M818,706 sh
Trails Edge Capital Partners, LP
$22.5M714,885 sh
TORONTO DOMINION BANK
$21.4M681,337 sh

Fund	Value	Shares
Samsara BioCapital, LLC	$54.0M	1,717,127
Casdin Capital, LLC	$48.6M	1,545,361
Redmile Group, LLC	$44.4M	1,412,199
RTW INVESTMENTS, LP	$42.8M	1,362,456
EcoR1 Capital, LLC	$40.0M	1,271,342
BlackRock, Inc.	$33.3M	1,057,983
BAKER BROS. ADVISORS LP	$31.2M	991,691
BALYASNY ASSET MANAGEMENT L.P.	$25.7M	818,706
Trails Edge Capital Partners, LP	$22.5M	714,885
TORONTO DOMINION BANK	$21.4M	681,337

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NGNE on your watchlist

Track score changes the day Neurogene Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NGNE a good stock to buy?

13F Pro's AI-powered analysis of Neurogene Inc. (NGNE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NGNE are available on the NGNE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NGNE is classified as a small company.

Which hedge funds own NGNE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NGNE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Neurogene Inc.'s investment landscape.